MED64 Application Note: Human Stem Cell-derived Cardiomyocyte Applications

MED64 Application Note: Human Stem Cell-derived Cardiomyocyte Applications

Keywords :
Human stem cell-derived cardiomyocytes (hSC-CMs); beat potential frequency; field potential duration (FPD)
Chronotropic drug effects; drug screening

Human stem cell-derived cardiomyocytes are a sample used by pharmaceutical companies and research institutions in research. Since human stem cell-derived cardiomyocytes have the same genetic background as primary human cardiomyocytes, their pharmacological properties should be very similar, so the platform combining human stem cell-derived cardiomyocytes and MED64 multi-electrode extracellular recording system has become a research. The mainstream of human hereditary myocardial disease models and drug screening.
Only the hSC-CMs need to be cultured on the MED recording electrode, and the basic electrophysiological parameters such as the beat frequency and the field potential time course can be recorded and extracted from the MED64 system . In addition, due to the non-invasive nature of the electrodes, stable recording can last for a very long time, so the effects of chronic drugs can also be measured on the MED64 system . Not only that, but MED64 can also use any electrode output stimulus to Pace hSC-CMs, so it can be used to study frequency-dependent or use-dependent drug effects.

References :

1.Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells.
Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers
DM, Robbins RC, Longaker MT, Wu JC.
Cell Stem Cell. 12(1): 101-13 (2013)

2.Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy.
Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG, Hu S, Wang L, Lee A, Pavlovic A, Lin S, Chen R, Hajjar RJ, Snyder MP, Dolmetsch RE, Butte MJ, Ashley EA, Longaker MT, Robbins RC, Wu JC.
Sci Transl Med. 4:130 (2012)

3. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval.
Yamazaki K, Hihara T, Taniguchi T, Kohmura N, Yoshinaga T, Ito M, Sawada K.
J Toxicol In Vitro. 26(2): 335-342 (2011)

4.Usefulness of field potential as a marker of embryonic stem cell-derived cardiomyocytes, and endpoint analysis of embryonic stem cell test.
Koseki N, Deguchi J, Yamada T, Funabashi H, Seki T.
Toxicol Sci. 35(6): 899-909 (2010)

5.Improvement of the embryonic stem cell test endpoint analysis by use of field potential detection.
Koseki N, Deguchi J, Yamada T, Funabashi H, Seki TJ Toxicol Sci. 35(5):619-29 (2010)

6. Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs.
Otsuji TG, Minami I, Kurose Y, Yamauchi K, Tada M, Nakatsuji N. Stem Cell Res. 4(3):201-13 (2010)